Company Overview and News


Add 0963
to your dashboard

Headline News

RPT-HK firms in China charm-push ahead of HK-Shenzhen investment link

2016-11-21 reuters
SHANGHAI, Nov 20 Scores of Hong Kong-listed companies - many small - are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

Hong Kong Firms Turn On the Charm Ahead of Shenzhen Investment Link

2016-11-20 fortune
Scores of Hong Kong-listed companies—many small—are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

Hong Kong firms in China charm-push ahead of Hong Kong-Shenzhen investment link

2016-11-20 channelnewsasia
SHANGHAI: Scores of Hong Kong-listed companies: many small: are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

Hong Kong firms in China charm-push ahead of Hong Kong-Shenzhen investment link

2016-11-20 reuters
SHANGHAI Scores of Hong Kong-listed companies - many small - are on a roadshow blitz in China to whet the appetite of mainland investors ahead of the launch of a cross-border investment link between Shenzhen and Hong Kong.

Global Facial Injectables Market 2016-2020

2016-10-12 prnewswire
NEW YORK, Oct. 12, 2016 /PRNewswire/ -- About Injectables Injectables are a combination of dermal fillers and Botox used in facial aesthetic treatments, which help reduce wrinkles and play a crucial role in rejuvenating facial skin for smoother and younger look. These are injected under the skin or lips to plump up the tissues and gently lift it to restore collagen lost due to aging. Collagen and HA provide essential support to skin and help it retain its elasticity.

Week In Review: Korea's Hanmi Signs $4.2 Billion Deal With Sanofi

2016-09-18 seekingalpha
Hanmi Pharma (KSE: 128940) of Korea out-licensed global rights for three long-acting diabetes drugs to Sanofi (NYSE: SNY) in a deal worth $4.2 billion (see story). Hanmi will receive $435 million upfront and up to $3.8 billion in milestones plus royalties on sales. Hanmi is on a roll. Earlier this year, the company out-licensed a novel lung cancer therapeutic to Boehringer Ingelheim for $730 million and sold the rights for an autoimmune drug to Lilly (NYSE: LLY) for $690 million.

Millennials' 'lunch-break cosmetics' spur China botox boom

2016-03-28 nzherald.co.nz
Fretting about frown lines and crow's feet can start early. In China, women in their 20s and 30s are spending on therapies to smooth their wrinkles -- a growing trend Union Medical Healthcare Ltd. wants to meet.